TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Blue Trust Inc.

Blue Trust Inc. grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 127.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,516 shares of the biopharmaceutical company’s stock after buying an additional 849 shares during the quarter. Blue Trust Inc.’s holdings in TG Therapeutics were worth $35,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TGTX. Marshall Wace LLP acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at about $36,501,000. Hood River Capital Management LLC acquired a new position in shares of TG Therapeutics in the 1st quarter valued at about $22,420,000. Point72 Asset Management L.P. purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $10,423,000. Assenagon Asset Management S.A. purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $8,698,000. Finally, Point72 Europe London LLP purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $2,860,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $26.90 on Friday. TG Therapeutics, Inc. has a 12 month low of $9.81 and a 12 month high of $26.99. The stock has a 50 day moving average of $23.51 and a two-hundred day moving average of $20.01. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The firm has a market cap of $4.16 billion, a P/E ratio of 44.10 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. During the same period in the previous year, the business earned ($0.34) EPS. TG Therapeutics’s quarterly revenue was up 357.0% on a year-over-year basis. On average, analysts expect that TG Therapeutics, Inc. will post 0.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several recent analyst reports. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group lifted their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.33.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.